May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
Intravitreal Brain-Derived Neurotrophic Factor in Rhegmatogenous Retinal Detachment
Author Affiliations & Notes
  • Y. Zhang
    Casey Eye Institute-OHSU, Portland, Oregon
  • D. Dhoot
    Casey Eye Institute-OHSU, Portland, Oregon
  • A. Lauer
    Casey Eye Institute-OHSU, Portland, Oregon
  • T. McFarland
    Casey Eye Institute-OHSU, Portland, Oregon
  • B. Appukuttan
    Casey Eye Institute-OHSU, Portland, Oregon
  • J. T. Stout
    Casey Eye Institute-OHSU, Portland, Oregon
  • Footnotes
    Commercial Relationships  Y. Zhang, None; D. Dhoot, None; A. Lauer, None; T. McFarland, None; B. Appukuttan, None; J.T. Stout, None.
  • Footnotes
    Support  Research to Prevent Blindness, Clayton Foundation for Research
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 5231. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Y. Zhang, D. Dhoot, A. Lauer, T. McFarland, B. Appukuttan, J. T. Stout; Intravitreal Brain-Derived Neurotrophic Factor in Rhegmatogenous Retinal Detachment. Invest. Ophthalmol. Vis. Sci. 2008;49(13):5231. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Brain-derived neurotrophic factor (BDNF) has been shown to induce neuroprotective and antiapoptotic processes to improve neurological function in animal models of stroke and retinal detachment (RD). Intravitreal injection of BDNF may provide a therapeutic approach to inhibit retinal neuronal cell death and loss of vision observed in RD. Little is known about endogenous intravitreal BDNF in normal human eyes or RD patients. The purpose of this study is to establish BDNF levels in vitreous samples collected from rhegmatogenous retinal detachment (RRD) patients and human eyes without disease.

Methods: : Undiluted vitreous samples were collected from RRD patients prior to pars plana vitrectomy, and stored immediately at -80ºC. Vitreous collected from fresh donor eyes without documented eye disease served as controls. The concentration of total protein within each vitreous sample was determined with a BCA assay kit. The vitreal BDNF concentration in RRD samples and controls were measured by enzyme-linked immunosorbent assay (ELISA), and normalized to total protein concentration. The BDNF/total protein ratios were statistically analyzed using a 2-tailed t-test.

Results: : The BDNF levels detected within the vitreous samples ranged from 4.8pg/ml to 11.8pg/ml. The BDNF/total protein ratio in the RRD group was 2.49±0.44 and found to be significantly higher than that of the control group which was 1.42±0.61, (p=0.042).

Conclusions: : BDNF is present at low levels within normal human vitreous. A higher level of intravitreal BDNF in RRD patients may indicate a natural cell survival response initiated by the RRD. Increasing the vitreal levels of BDNF, either exogenously or endogenously, may prove beneficial for protecting neurons in a detached retina as well as retinal neurodegenerative disorders.

Keywords: retinal detachment • vitreous • neuropeptides 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×